Clinical trials reported by American Society of Clinical Oncology indicate that Olaparib given to women with BRCA mutated advanced breast cancer gives them significant extra time before it progresses. It had a typical time to progression of 7 months compared to 4.2 months for chemotherapy. The drug was developed by UK Scientists.